{"id":559931,"date":"2021-02-09T03:50:35","date_gmt":"2021-02-09T03:50:35","guid":{"rendered":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/"},"modified":"2021-02-09T03:50:35","modified_gmt":"2021-02-09T03:50:35","slug":"gsk-only-has-eyes-for-hikma","status":"publish","type":"post","link":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/","title":{"rendered":"GSK only has eyes for Hikma"},"content":{"rendered":"

<\/a> GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and <\/strong>Acdima<\/a><\/strong> for its Egypt arm<\/strong>, focusing instead on talks with Hikma Pharma<\/a>, according to regulatory filings (here<\/a> and here<\/a> \u2014 pdfs). GSK said the decision is meant to minimize disruption to the business and save time and resources that would have been spent on due diligence and negotiations with Acdima and Rameda. GSK is considering selling its shares as part of a comprehensive agreement that would also include operations outside the listed entity and its business in Tunisia, the filing says.<\/p>\n

Having multiple suitors has done good things for GSK\u2019s shares on the EGX<\/strong>, which are up 141% year-to-date<\/a> on the back of the interest in its sale. The shares were trading at EGP 40.50 at market close yesterday.<\/p>\n

Background:<\/strong> The bidding war for the majority stake in GSK\u2019s Egypt commercialization and manufacturing business kicked off last week, when Acdima<\/a> and Rameda<\/a> announced within a day of each other that they\u2019re interested in a transaction. The two companies\u2019 announcements came a week after GSK announced that it was in negotiations<\/a> with LSE-listed Hikma Pharma<\/a> for the same 91.2% stake in its pharma and manufacturing business in Egypt and its Tunisia business. A timeline for the acquisition and the potential value of the purchase have yet to be disclosed.<\/p>\n","protected":false},"excerpt":{"rendered":"

GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and Acdima for its Egypt arm, focusing instead on talks with Hikma Pharma, according to regulatory filings (here and here \u2014 pdfs). GSK said the decision is meant to minimize disruption to the business and save time and resources that would have been spent on due […]<\/p>\n","protected":false},"author":1,"featured_media":559932,"comment_status":"closed","ping_status":"open","sticky":false,"template":"single-feature.php","format":"standard","meta":{"_acf_changed":false,"newspack_ads_suppress_ads":false,"newspack_popups_has_disabled_popups":false,"newspack_sponsor_sponsorship_scope":"","newspack_sponsor_native_byline_display":"inherit","newspack_sponsor_native_category_display":"inherit","newspack_sponsor_underwriter_style":"inherit","newspack_sponsor_underwriter_placement":"inherit","ep_exclude_from_search":false,"_primary_brand":0,"newspack_featured_image_position":"","newspack_post_subtitle":"","newspack_article_summary_title":"Overview:","newspack_article_summary":"","newspack_hide_updated_date":false,"newspack_show_updated_date":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[7363],"tags":[3706,72,1076,575,7128,427,449],"brand":[],"newspack_spnsrs_tax":[],"class_list":["post-559931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ma-watch","tag-acdima","tag-enterpriseam","tag-glaxosmithkline","tag-hikma-pharma","tag-ma-watch","tag-pharma","tag-rameda-pharma","wpautop","entry"],"acf":{"mongo_id":"ff646872-fe4d-42cb-9c86-ab3420e60774","is_powered_by":true,"story_type":"1","photo_url":"https:\/\/ent.news\/2021\/2\/153.jpg","photo_position":"above","related_issue":[559920],"teaser":"","voice_url":""},"yoast_head":"\nGSK only has eyes for Hikma - EnterpriseAM Egypt<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK only has eyes for Hikma\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and Acdima for its Egypt arm, focusing instead on talks with Hikma Pharma, according to regulatory filings (here and here \u2014 pdfs). GSK said the decision is meant to minimize disruption to the business and save time and resources that would have been spent on due […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\" \/>\n<meta property=\"og:site_name\" content=\"EnterpriseAM Egypt\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-09T03:50:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1\" \/>\n<meta name=\"author\" content=\"enterpriseam admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enterpriseam admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\"},\"author\":{\"name\":\"enterpriseam admin\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d\"},\"headline\":\"GSK only has eyes for Hikma\",\"datePublished\":\"2021-02-09T03:50:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\"},\"wordCount\":223,\"publisher\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#organization\"},\"image\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1\",\"keywords\":[\"ACDIMA\",\"EnterpriseAM\",\"GlaxoSmithKline\",\"Hikma Pharma\",\"M&A Watch\",\"pharma\",\"Rameda Pharma\"],\"articleSection\":[\"M&A WATCH\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\",\"url\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\",\"name\":\"GSK only has eyes for Hikma - EnterpriseAM Egypt\",\"isPartOf\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1\",\"datePublished\":\"2021-02-09T03:50:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/enterpriseam.com\/egypt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK only has eyes for Hikma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#website\",\"url\":\"https:\/\/enterpriseam.com\/egypt\/\",\"name\":\"EnterpriseAM\",\"description\":\"The State of the Nation\",\"publisher\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/enterpriseam.com\/egypt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#organization\",\"name\":\"EnterpriseAM\",\"url\":\"https:\/\/enterpriseam.com\/egypt\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ent.news\/internal\/240894.svg\",\"contentUrl\":\"https:\/\/ent.news\/internal\/240894.svg\",\"caption\":\"EnterpriseAM\"},\"image\":{\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d\",\"name\":\"enterpriseam admin\",\"sameAs\":[\"http:\/\/enterpriseam.testing.projectsarea.com\"],\"url\":\"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK only has eyes for Hikma - EnterpriseAM Egypt","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/","og_locale":"en_US","og_type":"article","og_title":"GSK only has eyes for Hikma","og_description":"GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and Acdima for its Egypt arm, focusing instead on talks with Hikma Pharma, according to regulatory filings (here and here \u2014 pdfs). GSK said the decision is meant to minimize disruption to the business and save time and resources that would have been spent on due […]","og_url":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/","og_site_name":"EnterpriseAM Egypt","article_published_time":"2021-02-09T03:50:35+00:00","og_image":[{"url":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1","type":"","width":"","height":""}],"author":"enterpriseam admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enterpriseam admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#article","isPartOf":{"@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/"},"author":{"name":"enterpriseam admin","@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d"},"headline":"GSK only has eyes for Hikma","datePublished":"2021-02-09T03:50:35+00:00","mainEntityOfPage":{"@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/"},"wordCount":223,"publisher":{"@id":"https:\/\/enterpriseam.com\/egypt\/#organization"},"image":{"@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1","keywords":["ACDIMA","EnterpriseAM","GlaxoSmithKline","Hikma Pharma","M&A Watch","pharma","Rameda Pharma"],"articleSection":["M&A WATCH"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/","url":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/","name":"GSK only has eyes for Hikma - EnterpriseAM Egypt","isPartOf":{"@id":"https:\/\/enterpriseam.com\/egypt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage"},"image":{"@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1","datePublished":"2021-02-09T03:50:35+00:00","breadcrumb":{"@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#primaryimage","url":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1","contentUrl":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1"},{"@type":"BreadcrumbList","@id":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/09\/gsk-only-has-eyes-for-hikma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/enterpriseam.com\/egypt\/"},{"@type":"ListItem","position":2,"name":"GSK only has eyes for Hikma"}]},{"@type":"WebSite","@id":"https:\/\/enterpriseam.com\/egypt\/#website","url":"https:\/\/enterpriseam.com\/egypt\/","name":"EnterpriseAM","description":"The State of the Nation","publisher":{"@id":"https:\/\/enterpriseam.com\/egypt\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/enterpriseam.com\/egypt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/enterpriseam.com\/egypt\/#organization","name":"EnterpriseAM","url":"https:\/\/enterpriseam.com\/egypt\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/","url":"https:\/\/ent.news\/internal\/240894.svg","contentUrl":"https:\/\/ent.news\/internal\/240894.svg","caption":"EnterpriseAM"},"image":{"@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/enterpriseam.com\/egypt\/#\/schema\/person\/ca597032db7e4db868359c123cec256d","name":"enterpriseam admin","sameAs":["http:\/\/enterpriseam.testing.projectsarea.com"],"url":"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/"}]}},"featured_image_src":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?resize=600%2C400&ssl=1","featured_image_src_square":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?resize=600%2C600&ssl=1","author_info":{"display_name":"enterpriseam admin","author_link":"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/"},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/153.jpg?fit=%2C&ssl=1","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":565019,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/03\/14\/gsk-is-staying-put-for-now\/","url_meta":{"origin":559931,"position":0},"title":"GSK is staying put \u2014 for now","author":"enterpriseam admin","date":"14 March 2021","format":false,"excerpt":"GSK puts Egypt exit on the backburner: GlaxoSmithKline has shelved plans to sell its units in Egypt and Tunisia following the breakdown of talks with UK-listed Hikma Pharma, the company said in a disclosure (pdf) to the EGX today. The pharma giant initially wanted to sell its entire 91.2% stake\u2026","rel":"","context":"In "SPEED ROUND: M&A WATCH"","block_context":{"text":"SPEED ROUND: M&A WATCH","link":"https:\/\/enterpriseam.com\/egypt\/category\/speed-round-ma-watch\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/internal\/536550.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":560791,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/03\/14\/gsk-hikma-end-acquisition-talks\/","url_meta":{"origin":559931,"position":1},"title":"GSK, Hikma end acquisition talks","author":"enterpriseam admin","date":"14 March 2021","format":false,"excerpt":"Hikma Pharma won\u2019t be acquiring GlaxoSmithKline\u2019s Egypt unit: GSK and Hikma Pharma have agreed to end talks over a takeover bid submitted in January by the UK-listed company that would have seen it acquire a majority stake in GSK\u2019s Egypt arm, both companies said (here and here \u2013 pdfs) on\u2026","rel":"","context":"In "M&A WATCH"","block_context":{"text":"M&A WATCH","link":"https:\/\/enterpriseam.com\/egypt\/category\/ma-watch\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2021\/3\/185.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":565042,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/03\/15\/gsk-egypt-rejects-acdimas-bid-to-start-due-diligence-closing-the-door-to-a-sale\/","url_meta":{"origin":559931,"position":2},"title":"GSK Egypt rejects Acdima\u2019s bid to start due diligence, closing the door to a sale","author":"enterpriseam admin","date":"15 March 2021","format":false,"excerpt":"GlaxoSmithKline Egypt\u2019s board of directors has rejected a request submitted by Acdima to start due diligence on the company, GSK said in an EGXdisclosure (pdf) this morning following a board meeting Sunday. Acdima submitted the request last week following the breakdown of talks between GSK and the UK\u2019s Hikma Pharma.This\u2026","rel":"","context":"In "SPEED ROUND: M&A WATCH"","block_context":{"text":"SPEED ROUND: M&A WATCH","link":"https:\/\/enterpriseam.com\/egypt\/category\/speed-round-ma-watch\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2021\/3\/473.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":559722,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/02\/a-bidding-war-for-gsks-egyptian-arm\/","url_meta":{"origin":559931,"position":3},"title":"A bidding war for GSK\u2019s Egyptian arm?","author":"enterpriseam admin","date":"2 February 2021","format":false,"excerpt":"Acdima may have just touched off a bidding war for GlaxoSmithKline's Egypt business, according to a regulatory filing (pdf) yesterday, less than a week after the global player revealed that Hikma was interested in a transaction. Acdima, a pharma industry investor focused on Arab countries, plans to make an offer\u2026","rel":"","context":"In "M&A WATCH"","block_context":{"text":"M&A WATCH","link":"https:\/\/enterpriseam.com\/egypt\/category\/ma-watch\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/37.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":559757,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/02\/03\/rameda-throws-its-hat-in-the-ring-for-gsks-egypt-business\/","url_meta":{"origin":559931,"position":4},"title":"Rameda throws its hat in the ring for GSK\u2019s Egypt business","author":"enterpriseam admin","date":"3 February 2021","format":false,"excerpt":"Ladies and gentlemen, we have a good, old-fashioned bidding war: Rameda Pharma is the latest to show interest in GlaxoSmithKline's Egypt business, joining LSE-listed Hikma Pharma and pharma industry investor Acdima \u2014 who are both planning their own bids. The company has submitted a non-binding letter of interest to GSK\u2026","rel":"","context":"In "M&A WATCH"","block_context":{"text":"M&A WATCH","link":"https:\/\/enterpriseam.com\/egypt\/category\/ma-watch\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/2021\/2\/58.jpg?fit=%2C&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":560822,"url":"https:\/\/enterpriseam.com\/egypt\/2021\/03\/15\/what-were-tracking-on-15-march-2021\/","url_meta":{"origin":559931,"position":5},"title":"What we\u2019re tracking on 15 March 2021","author":"enterpriseam admin","date":"15 March 2021","format":false,"excerpt":"Good morning, friends, and welcome to another brisk news day in which M&A news takes a back seat to the latest developments in the pandemic and the launch of an EGP 100 bn program to offer 30-year mortgages to low- and middle-income earners with subsidized rates. *** CATCH UP QUICK\u2026","rel":"","context":"In "What We're Tracking Today"","block_context":{"text":"What We're Tracking Today","link":"https:\/\/enterpriseam.com\/egypt\/category\/what-were-tracking-today\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/ent.news\/internal\/536550.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/posts\/559931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/comments?post=559931"}],"version-history":[{"count":0,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/posts\/559931\/revisions"}],"acf:post":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/issue\/559920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/media\/559932"}],"wp:attachment":[{"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/media?parent=559931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/categories?post=559931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/tags?post=559931"},{"taxonomy":"brand","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/brand?post=559931"},{"taxonomy":"newspack_spnsrs_tax","embeddable":true,"href":"https:\/\/enterpriseam.com\/egypt\/wp-json\/wp\/v2\/newspack_spnsrs_tax?post=559931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}